Illumina Inc.
ILMNBusiness Overview
source: coverage-next-full ticker: ILMN step: "01" title: Business Overview — Illumina, Inc. created: 2026-05-29
Step 01 — Business Overview: Illumina, Inc. (ILMN)
Company Summary
Illumina, Inc. is the world's dominant provider of next-generation sequencing (NGS) technology, controlling an estimated 80%+ of the global NGS market. Founded in 1998 and headquartered in San Diego, California, the company designs, develops, manufactures, and markets integrated systems for genetic analysis — spanning instruments, consumables (reagent kits, flow cells), software, and services.
Illumina's technology underpins virtually every major advance in genomics: population-scale sequencing initiatives, oncology liquid biopsy tests, NIPT (non-invasive prenatal testing), pharmacogenomics, rare disease diagnosis, agricultural genomics, and microbiome research. Its platforms are embedded in thousands of labs across hospitals, universities, biopharma companies, and government programs globally.
Business Model
Razor-and-Blade: Illumina sells or places sequencing instruments (razors), then generates recurring, high-margin revenue from consumables — reagent kits and flow cells that customers must repurchase with each sequencing run (blades). Instruments are priced $10K–$1M+ depending on throughput; consumables generate ~70–72% of total revenue annually.
Lock-In Dynamics: Once a lab installs Illumina instruments, switching costs are extremely high:
- Retraining staff and revalidating workflows is costly and time-consuming
- Clinical labs face regulatory recertification if they switch platforms
- Decades of published scientific literature built on Illumina chemistry creates methodology lock-in
- DRAGEN bioinformatics software is deeply integrated into sequencing workflows
Segments and Product Lines
Reporting Structure
Post-GRAIL divestiture (June 2024), Illumina reports as a single operating segment (Sequencing). Revenue is broken out by product type and end market in disclosures.
Product Type Revenue (FY2025)
| Product Type | Revenue | % of Total |
|---|---|---|
| Consumables | ~$3,040M | ~70% |
| Instruments | ~$780M | ~18% |
| Services | ~$523M | ~12% |
| Total | $4,343M | 100% |
Key Platforms
| Platform | Use Case | Position |
|---|---|---|
| NovaSeq X / X Plus | Ultra-high throughput (WGS, population sequencing, clinical) | Flagship; launched 2023; transformative cost reduction |
| NovaSeq 6000 | High throughput; predecessor platform | Sunset/replacement cycle underway |
| NextSeq 2000 | Mid-throughput (oncology panels, targeted sequencing) | Workhorse for clinical labs |
| MiSeq / MiniSeq | Low-throughput (targeted panels, amplicon sequencing) | Entry-level / benchtop |
| iSeq 100 | Ultra-low throughput | Point-of-care/education |
| DRAGEN | On-instrument bioinformatics acceleration | Software differentiation |
| SomaLogic SomaScan | Proteomics (7,000–11,000 protein measurement) | New (acquired Jan 2026); multiomics strategy |
End Market Breakdown (FY2025 est.)
- Clinical (~55%): Oncology (somatic/germline), NIPT, rare disease, pharmacogenomics
- Research (~45%): Academic, government (NIH-funded), biopharma R&D
Geographic Revenue (FY2025 est.)
| Region | Revenue | % of Total | Growth YoY |
|---|---|---|---|
| Americas | ~$1,780M | ~41% | +3–4% |
| EMEA | ~$1,390M | ~32% | +2–3% |
| Asia-Pacific | ~$1,173M | ~27% | -5–8% (China drag) |
| China (included above) | ~$250M | ~6% | ~-20% (UEL impact) |
GRAIL Chapter (2021–2024)
The most defining event of recent Illumina history was the GRAIL saga:
- Background: GRAIL was founded by Illumina in 2016 as a spin-off focused on multi-cancer early detection using liquid biopsy. Illumina re-acquired GRAIL in August 2021 for ~$8.0B.
- Regulatory opposition: The FTC and EU Competition Commission opposed the acquisition. The EU blocked it outright; the FTC issued an administrative complaint. Illumina defied the EU Order — a historic confrontation that generated billions in fines and massive board/management distraction.
- Board/CEO turnover: CEO Francis deSouza resigned in June 2023 after shareholder pressure. Carl Icahn waged a proxy campaign, placing new board members. The board undertook a strategic review.
- Divestiture: In October 2023, Illumina announced it would divest GRAIL. The divestiture was completed June 24, 2024: 85.5% of GRAIL was spun off to Illumina shareholders as GRAIL stock (now trading NASDAQ: GRAL); Illumina retained ~14.5%.
- Financial damage: Cumulative impairments on GRAIL exceeded $4B. Operating losses from GRAIL 2021–2024 were substantial. The distraction cost Illumina strategic execution during a critical window of NovaSeq X launch.
Strategic Positioning Post-GRAIL
Under CEO Jacob Thaysen (appointed August 2023, permanent appointment March 2024):
- Focus on core sequencing: Simplifying portfolio, driving NovaSeq X adoption
- Cost discipline: R&D rationalized from 27% to 22% of revenue; SG&A flat
- Clinical acceleration: Building out oncology, NIPT, and rare disease pathways
- Multiomics: SomaLogic acquisition (closed Jan 2026) adds proteomics capability — positioning for integrated multi-omics workflows
- China mitigation: Driving ex-China growth to offset ongoing headwinds from UEL designation
Key Customers
- Large genome centers (BGI/CNGB, Genomics England, Garvan Institute)
- Reference laboratories (LabCorp, Quest, Sonic Healthcare, Mayo Clinic)
- Hospital/health system labs (mass adoption for oncology testing)
- Academic research institutions (MIT, Broad Institute, Wellcome Sanger)
- Pharmaceutical and biotech companies (drug discovery, companion diagnostics)
- Government programs (NIH, UK Biobank, All of Us Research Program)
Competitive Position Summary
Illumina occupies a near-monopoly position in short-read NGS with ~80%+ market share. The company benefits from:
- 25+ years of installed base and consumable dependency
- Industry-standard chemistry (SBS — sequencing by synthesis)
- IP portfolio of 3,000+ patents
- Trusted brand in regulated clinical markets
- Scale advantages in manufacturing and R&D
Financial Snapshot
source: coverage-next-full ticker: ILMN step: "04" title: Financial Snapshot — 5-Year P&L Summary created: 2026-05-29
Step 04 — Financial Snapshot: 5-Year P&L Summary
Key Caveat: GRAIL Distortion
FY2021–FY2024 financials are heavily distorted by GRAIL (acquisition August 2021, divestiture June 2024). GAAP operating income and net income reflect massive impairment charges ($3.9B in FY2022, additional impairments in FY2023), GRAIL operating losses, and a disposal loss in FY2024 Q2. Adjusted/core metrics are the most relevant for ongoing analysis. FY2025 is the first clean year as a pure-play sequencing company.
Income Statement Summary (GAAP)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM (Q1 2026) |
|---|---|---|---|---|---|---|
| Revenue | $4,526M | $4,584M | $4,504M | $4,372M | $4,343M | $4,393M |
| YoY Growth | +39% | +1.3% | -1.7% | -2.9% | -0.7% | +1.3% |
| Gross Profit | $3,154M | $2,972M | $2,744M | $2,861M | $2,870M | $2,908M |
| Gross Margin | 69.7% | 64.8% | 60.9% | 65.5% | 66.1% | 66.2% |
| R&D Expense | $(1,060M) | $(1,321M) | $(1,354M) | $(1,107M) | $(967M) | $(953M) |
| SG&A Expense | $(1,044M) | $(1,210M) | $(1,108M) | $(1,062M) | $(1,086M) | $(1,104M) |
| Operating Income (GAAP) | $(123M) | $(4,179M) | $(1,069M) | $(833M) | $807M | $851M |
| Operating Margin | (2.7%) | (91.2%) | (23.7%) | (19.1%) | 18.6% | 19.4% |
| Interest & Other | ~$(82M) | ~$(80M) | ~$(85M) | ~$(60M) | ~$(55M) | ~$(50M) |
| Tax | — | — | — | — | ~$(100M) | ~$(100M) |
| Net Income (GAAP) | $762M | $(4,404M) | $(1,161M) | $(1,223M) | $850M | $853M |
| Diluted EPS (GAAP) | $5.04 | $(28.00) | $(7.34) | $(7.69) | $5.45 | $5.52 |
Notes on GAAP distortions:
- FY2021 net income positive despite operating losses — reflects deferred tax benefits and other items
- FY2022 operating loss: includes ~$3.9B goodwill impairment on GRAIL
- FY2023 operating loss: includes ~$700M+ additional impairments and GRAIL operating losses
- FY2024 Q2 operating loss: ~$1.7B disposal loss on GRAIL divestiture
- FY2024 Q3 operating income spike ($741M in one quarter) reflects GRAIL derecognition gain
Adjusted (Non-GAAP) Operating Income — Core Business
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|---|---|
| Revenue | $4,526M | $4,584M | $4,504M | $4,372M | $4,343M | ~$4,520M |
| Non-GAAP Gross Margin | ~70% | ~66% | ~64% | ~66% | ~68% | ~68-69% |
| Non-GAAP Operating Income | ~$1,200M | ~$1,050M | ~$850M | ~$950M | ~$1,050M | ~$1,200M |
| Non-GAAP Operating Margin | ~26% | ~23% | ~19% | ~22% | ~24% | ~26% |
| Non-GAAP EPS | ~$7.50 | ~$5.70 | ~$4.30 | ~$5.20 | ~$6.50 | ~$5.05–5.20 |
Exclusions from Non-GAAP: Stock-based compensation (~$300–400M/yr), amortization of acquired intangibles, GRAIL-related items, restructuring charges, impairments
Gross Margin Analysis
| Driver | Direction | Magnitude |
|---|---|---|
| GRAIL consolidation (FY2022-Q2 2024) | Dilutive | ~300–500 bps drag |
| NovaSeq X ramp (higher-margin consumables) | Accretive | +100–200 bps |
| Manufacturing efficiency | Accretive | +50–100 bps |
| China revenue decline | Slightly dilutive | ~30–50 bps |
| Product mix (consumable % rising) | Accretive | Structural tailwind |
Core gross margin expanded from ~60.9% (FY2023 trough, GRAIL-burdened) to 66.1% (FY2025, clean). Management targets 68–70% longer-term as NovaSeq X consumables mature.
Operating Expense Trends
| OpEx Category | FY2023 | FY2024 | FY2025 | Commentary |
|---|---|---|---|---|
| R&D | $1,354M (30.1%) | $1,107M (25.3%) | $967M (22.3%) | Significant reduction post-GRAIL; right-sizing |
| SG&A | $1,108M (24.6%) | $1,062M (24.3%) | $1,086M (25.0%) | Relatively stable |
| Total OpEx | $2,462M (54.7%) | $2,169M (49.6%) | $2,053M (47.3%) | Positive leverage |
Key insight: R&D rationalization from 30% → 22% of revenue is the largest driver of the EBIT margin recovery. Management target is ~22–24% R&D long-term while maintaining innovation pace.
P&L Summary Table (FY2025 — Clean Year)
| Line Item | FY2025 | % of Revenue |
|---|---|---|
| Revenue | $4,343M | 100.0% |
| Cost of Revenue | $(1,473M) | 33.9% |
| Gross Profit | $2,870M | 66.1% |
| R&D | $(967M) | 22.3% |
| SG&A | $(1,086M) | 25.0% |
| Total Operating Expenses | $(2,053M) | 47.3% |
| EBIT | $807M | 18.6% |
| Interest Expense, net | ~$(55M) | |
| Other income | ~$100M | |
| Pre-tax Income | ~$852M | |
| Income Tax | ~$(2M) | |
| Net Income | $850M | 19.6% |
| Diluted EPS | $5.45 | |
| Diluted Shares | 156.0M |
Key Financial Ratios (FY2025 / TTM)
| Ratio | FY2025 | TTM | Commentary |
|---|---|---|---|
| Gross Margin | 66.1% | 66.2% | Expanding; target 68–70% |
| EBIT Margin | 18.6% | 19.4% | Recovery from GRAIL era; target 26% by 2027 |
| Net Margin | 19.6% | 19.4% | |
| FCF Margin | 21.4% | 22.2% | Strong; >100% net income conversion |
| FCF/Revenue | 21.4% | 22.2% | Exceptional for instruments company |
| R&D/Revenue | 22.3% | — | Well-funded innovation |
Financial Health Assessment
Strengths:
- Revenue stabilized at $4.3–4.4B; returning to growth in FY2026
- Gross margin recovery underway (60.9% trough → 66.1% → targeting 68–70%)
- FCF generation strong and improving ($283M → $709M → $931M in 3 years)
- Operating leverage now flowing through as GRAIL costs eliminated
- Balance sheet: $1.6B cash, $1.5B LT debt — manageable
Risks:
- Revenue near peak (FY2021 was $4.5B; FY2025 still slightly below)
- R&D cuts could be short-sighted if competitive threats accelerate
- SomaLogic integration adds complexity and integration risk to clean story
- China revenue headwinds persist
Verdict: The GAAP P&L is finally clean. Illumina's core economics — 66%+ gross margins, 22%+ EBIT margins on normalized basis, 21%+ FCF margins — are exceptional for an instrument company. The path to 26% EBIT margin (management 2027 target) is credible via continued consumable mix-up and OpEx leverage.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $ILMN.